IRAK4-IN-9 (compound 73) is a highly potent inhibitor of IRAK4, displaying an impressive IC50 value of 1.5 nM. By blocking MyD88-dependent signaling, IRAK4-IN-9 exhibits promising potential for the investigation of inflammatory diseases, autoimmune diseases, and cancer [1].
IRAK4-IN-17 (Compound 5) is a highly potent inhibitor of IRAK4, exhibiting an impressive IC50 value of 1.3 nM [1]. This compound is particularly valuable for research focused on large B-cell lymphoma (DLBCL) [1].